Company profile
Traws Pharma, Inc.
NASDAQ:TRAWBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Narazaciclib | phase1 | — | 1 | unknown |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (35)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06757738 | phase1 | completed | 2024-08-13 | 2025-01-16 | Traws Pharma, Inc. | A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers |
| NCT02562443 | phase3 | terminated | 2015-12-02 | 2020-07-26 | Traws Pharma, Inc. | Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA |
| NCT01125891 | phase1 | completed | 2009-01-01 | 2011-09-01 | Traws Pharma, Inc. | Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors |
| NCT02168725 | phase1 | terminated | 2014-06-01 | 2015-12-01 | Traws Pharma, Inc. | Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors |
| NCT07157007 | phase2 | recruiting | 2025-09-16 | 2026-02-01 | Traws Pharma, Inc. | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 |
FDA applications (0)
No records yet.